TY - JOUR
T1 - Characterization of readmission after allogeneic hematopoietic cell transplantation
AU - Yamaguchi, Kyosuke
AU - Inamoto, Yoshihiro
AU - Tajima, Kinuko
AU - Sakatoku, Kazuki
AU - Kuno, Masatomo
AU - Kawajiri, Akihisa
AU - Takemura, Tomonari
AU - Tanaka, Takashi
AU - Ito, Ayumu
AU - Kurosawa, Saiko
AU - Kim, Sung Won
AU - Fukuda, Takahiro
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.
PY - 2021/6
Y1 - 2021/6
N2 - To elucidate the incidence, causes, and risk factors associated with readmission due to transplant-related complications, we studied 213 consecutive patients who were discharged without progression of primary disease after their first allogeneic hematopoietic cell transplantation at our center between 2013 and 2016. The median patient age was 50 years (range, 18–71 years). Eighty-three patients had AML or MDS, 66 had lymphoma, 28 had ALL, 23 had ATL, and 13 had other diseases. The median duration of hospitalization for transplantation was 56 days (range 27–325 days). The cumulative incidences of readmission due to transplant-related complications were 8% at 30 days, 16% at 100 days, and 25% at 1 year after discharge. The most frequent cause of readmission was infection, followed by graft-versus-host disease throughout the first year. In multivariate analysis, steroid use at discharge was the only risk factor associated with readmission within 30 days, and steroid use at discharge, absolute lymphocyte count < 500/µl at discharge, and documented bacterial infection during admission were risk factors associated with readmission within 1 year. Our results indicated that factors during hospitalization or discharge, but not at transplantation, were associated with readmission. Patients with these risk factors should be monitored carefully after discharge.
AB - To elucidate the incidence, causes, and risk factors associated with readmission due to transplant-related complications, we studied 213 consecutive patients who were discharged without progression of primary disease after their first allogeneic hematopoietic cell transplantation at our center between 2013 and 2016. The median patient age was 50 years (range, 18–71 years). Eighty-three patients had AML or MDS, 66 had lymphoma, 28 had ALL, 23 had ATL, and 13 had other diseases. The median duration of hospitalization for transplantation was 56 days (range 27–325 days). The cumulative incidences of readmission due to transplant-related complications were 8% at 30 days, 16% at 100 days, and 25% at 1 year after discharge. The most frequent cause of readmission was infection, followed by graft-versus-host disease throughout the first year. In multivariate analysis, steroid use at discharge was the only risk factor associated with readmission within 30 days, and steroid use at discharge, absolute lymphocyte count < 500/µl at discharge, and documented bacterial infection during admission were risk factors associated with readmission within 1 year. Our results indicated that factors during hospitalization or discharge, but not at transplantation, were associated with readmission. Patients with these risk factors should be monitored carefully after discharge.
UR - http://www.scopus.com/inward/record.url?scp=85098889051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098889051&partnerID=8YFLogxK
U2 - 10.1038/s41409-020-01190-w
DO - 10.1038/s41409-020-01190-w
M3 - Article
C2 - 33414511
AN - SCOPUS:85098889051
SN - 0268-3369
VL - 56
SP - 1335
EP - 1340
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 6
ER -